NCT02104063View on ClinicalTrials.gov

Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]

CompletedOBSERVATIONAL
Enrollment

78

Participants

Timeline

Start Date

July 22, 2013

Primary Completion Date

July 22, 2016

Study Completion Date

July 22, 2016

Conditions
Squamous Cell Carcinoma of the Penis
Interventions
PROCEDURE

MRI-PET

Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.

Trial Locations (1)

NW1 2BU

University College London Hospitals, London

All Listed Sponsors
lead

Queen Mary University of London

OTHER

NCT02104063 - Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] | Biotech Hunter | Biotech Hunter